行情

ALXN

ALXN

亚力兄制药
NASDAQ

实时行情|Nasdaq Last Sale

105.89
-1.24
-1.16%
已收盘, 16:52 11/14 EST
开盘
107.37
昨收
107.13
最高
107.78
最低
104.52
成交量
160.37万
成交额
--
52周最高
141.86
52周最低
92.56
市值
234.32亿
市盈率(TTM)
17.54
分时
5日
1月
3月
1年
5年

分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALXN 新闻

  • The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
  • Zacks.19小时前
  • Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
  • Zacks.20小时前
  • Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why
  • Zacks.21小时前
  • 5 Most-Loved S&P 500 Stocks on Wall Street
  • Zacks.1天前

更多

所属板块

制药
-0.36%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

ALXN 简况

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
展开

Webull提供Alexion Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。